SARC006: Phase II Trial of Chemotherapy in Sporadic and Neurofibromatosis Type 1 Associated Chemotherapy-Naive Malignant Peripheral Nerve Sheath Tumors.
Christine S HighamSeth M SteinbergEva DombiArie PerryLee J HelmanScott M SchuetzeJoseph A LudwigArthur StaddonMohammed M MilhemDaniel RushingRobin L JonesMichael LivingstonStewart GoldmanChristopher MoertelLars WagnerDavid JanhoferChristina M AnnunziataDenise ReinkeLauren LongDavid ViskochilLarry BakerBrigitte C WidemannPublished in: Sarcoma (2017)
This trial was not powered to detect differences in response rates between NF1 and sporadic MPNST. While the OR rate was lower in NF1 compared to sporadic MPNST, qualitative responses were similar, and disease stabilization was achieved in most patients.
Keyphrases
- peripheral nerve
- late onset
- signaling pathway
- amyotrophic lateral sclerosis
- end stage renal disease
- lps induced
- ejection fraction
- newly diagnosed
- oxidative stress
- locally advanced
- nuclear factor
- clinical trial
- peritoneal dialysis
- prognostic factors
- pi k akt
- open label
- early onset
- hiv infected
- radiation therapy
- inflammatory response
- phase iii
- toll like receptor
- patient reported